Zentalis Pharmaceuticals (ZNTL) Cash from Operations (2022 - 2026)
Zentalis Pharmaceuticals has reported Cash from Operations over the past 5 years, most recently at 32956000.0 for Q1 2026.
- For Q1 2026, Cash from Operations fell 0.98% year-over-year to 32956000.0; the TTM value through Mar 2026 reached 125567000.0, up 17.13%, while the annual FY2025 figure was 125247000.0, 26.7% up from the prior year.
- Cash from Operations for Q1 2026 was 32956000.0 at Zentalis Pharmaceuticals, down from 30940000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 26963000.0 in Q3 2025 and troughed at 79275000.0 in Q2 2023.
- A 5-year average of 41213882.35 and a median of 38665000.0 in 2023 define the central range for Cash from Operations.
- Biggest five-year swings in Cash from Operations: plummeted 84.24% in 2023 and later soared 55.67% in 2024.
- Year by year, Cash from Operations stood at 37329000.0 in 2022, then decreased by 8.76% to 40599000.0 in 2023, then increased by 2.21% to 39702000.0 in 2024, then rose by 22.07% to 30940000.0 in 2025, then dropped by 6.52% to 32956000.0 in 2026.
- Business Quant data shows Cash from Operations for ZNTL at 32956000.0 in Q1 2026, 30940000.0 in Q4 2025, and 26963000.0 in Q3 2025.